Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell Malignancies
Status:
Recruiting
Trial end date:
2023-11-30
Target enrollment:
Participant gender:
Summary
This is a phase I, interventional, single arm, open label, treatment study to evaluate the
safety and tolerability of anti-CD5 CART cells in patients with relapsed and/or refractory T
cell lymphoma or leukemia.
Phase:
Phase 1
Details
Lead Sponsor:
iCell Gene Therapeutics
Collaborators:
iCAR Bio iCAR Bio Therapeutics Ltd. Peking University Shenzhen Hospital